Hemab launches late-stage sutacimig study without control arm, diverging from FDA suggestion
The bleeding-disorder specialist has begun pivotal testing of its lead drug in Glanzmann thrombasthenia, choosing a trial format the US regulator had not encouraged, alongside two other pipeline updates.
Hemab Therapeutics has moved its lead candidate, sutacimig, into pivotal development for Glanzmann thrombasthenia, a rare inherited bleeding disorder. The company disclosed the start of the study, called SOLARA, with its third-quarter 2026 results on 10 November. Participants receive the drug as a weekly subcutaneous injection, and every patient gets the active treatment.
The format is the notable commercial and regulatory detail. According to Hemab, the US Food and Drug Administration recommended that it consider a randomised comparison. The company went the other way, saying a randomised study would be hard to run in so small a patient population. The material available does not say how the agency now regards the final design, so it is unclear whether the choice has been accepted.
Beyond SOLARA, Hemab said it has dosed the first participant in a Phase 1 trial of HMB-003 in heavy menstrual bleeding. It also released first clinical data for sutacimig in Factor VII deficiency, a second bleeding disorder. Details of those data were not available to us.
The material reviewed gave no enrolment targets, endpoints, efficacy results or financial figures, so the study's size, timelines and the company's cash position cannot be assessed from it.
Why it matters
- The gap between the FDA's randomisation suggestion and Hemab's uncontrolled design is a point regulatory teams in rare disease may want to watch at review.
- Payers and health technology assessment bodies often look for comparative evidence, so how a trial without a control arm is judged on reimbursement is an open question for market access.
- Early Factor VII deficiency data hint that sutacimig could reach beyond Glanzmann thrombasthenia, but only preliminary information is public.
Company's press release (SEC filing): Hemab Therapeutics Holdings, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
